CA2646589C - Inhibition of tumour growth - Google Patents

Inhibition of tumour growth Download PDF

Info

Publication number
CA2646589C
CA2646589C CA2646589A CA2646589A CA2646589C CA 2646589 C CA2646589 C CA 2646589C CA 2646589 A CA2646589 A CA 2646589A CA 2646589 A CA2646589 A CA 2646589A CA 2646589 C CA2646589 C CA 2646589C
Authority
CA
Canada
Prior art keywords
tumour
use according
growth
cells
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2646589A
Other languages
English (en)
French (fr)
Other versions
CA2646589A1 (en
Inventor
Oeystein Rekdal
John Sigurd Svendsen
Baldur Sveinbjoernsson
Gerd Berge
Live Tone Eliassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lytix Biopharma AS
Original Assignee
Lytix Biopharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma AS filed Critical Lytix Biopharma AS
Publication of CA2646589A1 publication Critical patent/CA2646589A1/en
Application granted granted Critical
Publication of CA2646589C publication Critical patent/CA2646589C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2646589A 2006-03-21 2007-03-21 Inhibition of tumour growth Expired - Fee Related CA2646589C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0605685.7 2006-03-21
GBGB0605685.7A GB0605685D0 (en) 2006-03-21 2006-03-21 Inhibition of tumour growth
PCT/GB2007/000993 WO2007107748A2 (en) 2006-03-21 2007-03-21 Inhibition of tumour growth

Publications (2)

Publication Number Publication Date
CA2646589A1 CA2646589A1 (en) 2007-09-27
CA2646589C true CA2646589C (en) 2016-05-03

Family

ID=36383910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2646589A Expired - Fee Related CA2646589C (en) 2006-03-21 2007-03-21 Inhibition of tumour growth

Country Status (8)

Country Link
EP (1) EP2010204A2 (OSRAM)
JP (1) JP2009530359A (OSRAM)
CN (1) CN101466391A (OSRAM)
AU (1) AU2007228574B2 (OSRAM)
CA (1) CA2646589C (OSRAM)
GB (1) GB0605685D0 (OSRAM)
NO (1) NO20084053L (OSRAM)
WO (1) WO2007107748A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821616D0 (en) * 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ
JP6767096B2 (ja) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
CA2976377A1 (en) * 2015-02-12 2016-08-18 The Johns Hopkins University Inhibition of yap for breaking tumor immune tolerance
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
EP4637800A1 (en) 2022-12-20 2025-10-29 Lytix Biopharma AS Compositions comprising an oncolytic peptide and chitosan
WO2024133580A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Medical products containing an aqueous formulation of a peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
DE3854476T2 (de) * 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
US5773413A (en) * 1993-06-04 1998-06-30 Demeter Biotechnologies, Ltd. Method of combating mammalian neoplasias, and lytic peptides therefor
IL113244A0 (en) * 1994-04-08 1995-07-31 Demeter Biotech Ltd Method of combating mammalian neoplasia and lytic peptides therefor
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides

Also Published As

Publication number Publication date
WO2007107748A3 (en) 2007-12-06
GB0605685D0 (en) 2006-05-03
JP2009530359A (ja) 2009-08-27
AU2007228574A1 (en) 2007-09-27
NO20084053L (no) 2008-11-28
EP2010204A2 (en) 2009-01-07
AU2007228574B2 (en) 2013-06-20
WO2007107748A2 (en) 2007-09-27
CA2646589A1 (en) 2007-09-27
CN101466391A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
CA2646589C (en) Inhibition of tumour growth
US12239686B2 (en) Immune checkpoint inhibitor combinations
US20250002854A1 (en) Methods of generating populations of tumour-infiltrating t cells
EP1712238A1 (en) Anthracyclin induced immunogenic dead or dying cells composition
BRPI0613185A2 (pt) revestimento de superfìcie celular com agentes ativos
US9109048B2 (en) Inhibition of tumor growth
WO2016091490A1 (en) Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics
CA3221194A1 (en) Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c)
US11123398B2 (en) Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics
Fidler Therapy of disseminated melanoma by liposome‐activated macrophages
RU2837689C2 (ru) Иммуноонкотерапевтическая композиция с применением адъюванта, включающего липопептиды и поли(i:c)
CN103974968A (zh) 免疫调节剂金属肽(immp)和包含其的组合物
Zhou et al. Blocking Blood Supply to Breast Carcinoma With a DNA Vaccine Encoding VEGF Receptor-2
Kim et al. High Efficacy of

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190321